NCT03656094 2019-12-09Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 InhibitorsSamsung Medical CenterPhase 2 Unknown98 enrolled
NCT01848613 2018-11-09VIVOSIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSPhase 4 Completed120 enrolled